Drug delivery nanomedicine, exemplified by micelles and nanoparticles roughly in the size range of 1-200 nm, have attracted much interest in the past 2-3 decades as alternative modalities for cancer treatment. The size of these drug delivery vehicles has been strongly correlated with their in vivo biodistribution, penetration in tumor tissue, and intracellular trafficking. It potentially has significant impact on their antitumor efficacy. However, it is challenging to make nanomedicine in large quanti-ties with controlled particle size and narrow particle size ranges, in particular for nanomedicine smaller than 50 nm. Here we report a novel drug delivery platform based on drug-silica nanoconju-gates (drug-NCs) that can be controlled fabricated at nearly any desired size between 20 and 200 nm, with extremely narrow particle size distribution, in multi-gram scale within a few hours. Several in vitro and in vivo studies demonstrated that the sizes of the drug-NCs have huge impact on cell uptake and tumor penetration; the drug-NCs with size of 20 nm outperform their counterparts with larger sizes, showing great promise in cancer therapy and diagnosis.
University of Illinois at Urbana-Champaign
Researchers should cite this work as follows:
Li Tang (2011), "Illinois BioNanotechnology Seminar Series Fall 2011: Precisely Size Controlled Drug-silica Nanoconjugate for Cancer Therapy," https://nanohub.org/resources/12440.